Dominick DiSabatino advises companies across the life sciences industry on regulatory strategy, compliance and risk management, helping organizations at every stage of development navigate FDA and related regulatory requirements while advancing value-focused business objectives. Drawing on substantial client-side secondment experience, Dominick brings an inside view of how regulatory, commercial, medical and compliance functions operate in practice—enabling him to deliver guidance that is both pragmatic and aligned with real-world business needs.
He works closely with executive leadership and governance committees within client organizations to support decision-making on development pathways, commercialization planning and enterprise-level compliance priorities. Dominick regularly counsels clients on FDA and FTC advertising and promotion requirements, product communications and the integration of compliant promotional practices across multifunctional teams. He also advises on OIG compliance program expectations and helps organizations build and refine frameworks that support sustainable, risk-adjusted operations.
In addition, Dominick has extensive experience advising on corporate transactions involving FDA-regulated assets. He supports investors, strategic acquirers and life sciences companies by:
- Assessing regulatory risk
- Evaluating product development and compliance status
- Structuring deal considerations that reflect the regulatory landscape for drugs, devices, biologics and combination products
Across his practice, Dominick is known for translating complex regulatory obligations into clear, actionable strategies tailored to each client’s technology, business model and stage of growth. His experience in FDA and life sciences regulatory matters fuels his service as a trusted advisor during inflection points where regulatory choices directly shape value, competitive positioning and long-term success.
